Powder: -20°C for 3 years | In solvent: -80°C for 1 year
α-Cyano-4-hydroxycinnamic acid (α-Cyano-4-hydroxycinnamic acid(α-CHCA)) 是非竞争性单羧酸盐转运蛋白 (MCTs) 抑制剂,可抑制线粒体丙酮酸转运蛋白,Ki 值为 6.3 μM。它可作为基质辅助激光解吸电离-飞行时间质谱 (MALDI-TOF) 分析的基质,可以促进肽离子化。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
50 mg | ¥ 313 | 现货 | ||
100 mg | ¥ 453 | 现货 | ||
200 mg | ¥ 659 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 185 | 现货 |
产品描述 | α-Cyano-4-hydroxycinnamic acid (α-Cyano-4-hydroxycinnamic acid(α-CHCA)) (α-CHCA) is an inhibitor of monocarboxylate transporter 1 (MCT1) that blocks pyruvate transport in rat heart mitochondria (IC50 : 1.5 μM). |
体外活性 | CHC在胶质瘤细胞中的有效性似乎依赖于单羧酸转运蛋白(MCTs)的膜表达。MCT1的下调在不同的胶质瘤细胞中显示了类似的效果,这支持了CHC作为MCT1抑制剂的观点。当CHC与替莫唑胺治疗结合使用时,在U251细胞中观察到了协同效应。在CAM体内模型中,CHC减小了肿瘤的大小和形成的血管数量[1]。 |
细胞实验 | Cells were plated into 96-well plates, at a density of 3 × 10^3 cells per well.?The effect of treatment with CHC (0.6–12 mM) on cell number (total biomass) was determined at 24, 48, and 72 h by the?sulforhodamine B assay (SRB, TOX-6).?IC50 values (CHC concentration that corresponds to 50% of cell growth inhibition) were estimated from 3 independent experiments, each one in triplicate, using GraphPad Software.?Cell proliferation assay was performed as previously described32 and assessed under the treatment conditions previously described, for 5 mM and 10 mM of CHC.?After CHC treatment, cells were incubated with BrdU and its incorporation was assessed at 450 nm (λref = 655 nm) .?Cell growth (total biomass) and cell proliferation for glioma siMCT1 cells and the effect of CHC (1.25–15 mM) on cell number were performed[1]. |
别名 | α-Cyano-4-hydroxycinnamic acid(α-CHCA), 2-氰基-4-羟基 |
分子量 | 189.17 |
分子式 | C10H7NO3 |
CAS No. | 28166-41-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 37 mg/mL (195.59 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 5.2863 mL | 26.4313 mL | 52.8625 mL | 132.1563 mL |
5 mM | 1.0573 mL | 5.2863 mL | 10.5725 mL | 26.4313 mL | |
10 mM | 0.5286 mL | 2.6431 mL | 5.2863 mL | 13.2156 mL | |
20 mM | 0.2643 mL | 1.3216 mL | 2.6431 mL | 6.6078 mL | |
50 mM | 0.1057 mL | 0.5286 mL | 1.0573 mL | 2.6431 mL | |
100 mM | 0.0529 mL | 0.2643 mL | 0.5286 mL | 1.3216 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
α-Cyano-4-hydroxycinnamic acid 28166-41-8 Membrane transporter/Ion channel Monocarboxylate transporter matrix-assisted MALDI-TOF matrix Inhibitor lactate a-Cyano-4-hydroxycinnamic acid applications MCTs pyruvate laser desorption α-Cyano-4-hydroxycinnamic acid(α-CHCA) spectrometry ionization Monocarboxylate Transporter a-Cyano-4-hydroxycinnamic acid(a-CHCA) transporter α Cyano 4 hydroxycinnamic acid 2-氰基-4-羟基 peptide inhibit alpha-Cyano-4-hydroxycinnamic acid alpha-Cyano-4-hydroxycinnamic acid(alpha-CHCA) αCyano4hydroxycinnamic acid facilitate inhibitor